Related Experiment Video
Updated: Aug 13, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
Published on: August 12, 2015
Investigations of antisense oligonucleotides targeted against bcl-2 RNAs
S Kitada1, T Miyashita, S Tanaka
1La Jolla Cancer Research Foundation, Cancer Research Center, California.
Abstract:
Expression of the bcl-2 gene becomes deregulated in many non-Hodgkin lymphomas as the result of t(14;18) chromosomal translocations. Because bcl-2 regulates the survival of cells, and because its over-expression is associated with cellular resistance to killing by chemotherapeutic drugs and gamma-irradiation, this gene and its mRNA and protein products represent ideal targets for designing novel therapeutic strategies for the treatment of cancer. Here we describe the effects of an 18-mer phosphodiester oligonucleotide that is complementary to the first 6 codons of the bcl-2 mRNA's open reading frame. When tested for inhibition of in vitro protein synthesis using RNAse-H-supplemented reticulocyte lysates and RNA prepared by in vitro transcription of a human bcl-2 cDNA, the bcl-2 antisense (AS) oligomer completely abolished Bcl-2 protein production at 10 microM, but had no effect on the in vitro translation of a chicken bcl-2 RNA that contained three mismatches relative to the oligomer binding site on the human bcl-2 RNA. A control 18-mer having the same base composition as the AS oligomer but with scrambled order (SC) was not inhibitory. Addition of AS and SC oligomers to cultures of a NIH-3T3 fibroblast cell line that had been stably infected with a recombinant retrovirus containing the same human bcl-2 cDNA used for in vitro transcription/translation experiments revealed concentration-dependent reductions in the relative levels of the 26-kD human Bcl-2 protein (as determined by immunoblotting) by the AS but not by the SC oligomer. Similar results were obtained when AS and SC oligomers were applied to a t(14;18)-containing lymphoma cell line SU-DHL-4 that was cultured in low-serum media. When used at 200 microM, the bcl-2 AS oligomer produced 84-95% reductions in Bcl-2 protein levels in SU-DHL-4 cells but had relatively little effect on the levels of other mitochondrial control proteins, suggesting that the inhibitory effects were specific. Treatment of SU-DHL-4 cells with AS oligomer lead to essentially complete loss of bcl-2 mRNA from cells within 1 day of addition to cultures, but presumably because of the long half-life of the Bcl-2 protein (approximately 14 h), commensurate reductions in Bcl-2 protein levels did not occur until 3 days.(ABSTRACT TRUNCATED AT 400 WORDS)
Insights
An antisense oligonucleotide targeting bcl-2 mRNA effectively reduced Bcl-2 protein production in cancer cells. This bcl-2 (B-cell lymphoma 2) targeting strategy shows promise for cancer therapy by inhibiting cell survival proteins.
Area of Science:
- Molecular Biology
- Cancer Research
- Antisense Technology
Background:
- Deregulation of the bcl-2 gene, often due to t(14;18) translocations, is common in non-Hodgkin lymphomas.
- Overexpression of bcl-2 contributes to cellular resistance to chemotherapy and radiation, making it a key target for cancer therapeutics.
- bcl-2 protein regulates cellular survival, and its modulation is critical for developing novel cancer treatment strategies.
Purpose of the Study:
- To investigate the efficacy of a novel 18-mer phosphodiester antisense (AS) oligonucleotide targeting the bcl-2 mRNA.
- To assess the specificity and effectiveness of the AS oligomer in inhibiting bcl-2 protein synthesis in vitro and in cell cultures.
- To evaluate the potential of bcl-2 antisense therapy for cancer treatment.
Main Methods:
- In vitro protein synthesis inhibition assays using RNAse-H-supplemented reticulocyte lysates and bcl-2 mRNA.
- Testing of the bcl-2 AS oligomer and a scrambled control (SC) oligomer on NIH-3T3 fibroblasts and t(14;18)-positive lymphoma cells (SU-DHL-4).
- Quantification of bcl-2 mRNA and protein levels using immunoblotting and assessment of specificity against other mitochondrial proteins.
Main Results:
- The bcl-2 AS oligomer completely abolished in vitro bcl-2 protein synthesis at 10 microM, showing specificity against mismatched RNA.
- Concentration-dependent reductions in Bcl-2 protein levels were observed in NIH-3T3 and SU-DHL-4 cells treated with the AS oligomer, but not the SC oligomer.
- Treatment of SU-DHL-4 cells with 200 microM AS oligomer resulted in 84-95% reduction in Bcl-2 protein, with minimal impact on other control proteins, and led to mRNA loss within 1 day, with protein reduction apparent by 3 days.
Conclusions:
- The bcl-2 antisense oligonucleotide is a specific and effective inhibitor of bcl-2 protein production.
- This study demonstrates the potential of antisense technology targeting bcl-2 for developing novel cancer therapies.
- The findings support bcl-2 as a viable therapeutic target in lymphomas and other cancers characterized by its overexpression.
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi

